Consequently, 10-HDA was implicated in inhibiting the target genes of the phosphoinositide-3-kinase-protein kinase B/AKT (PI3K-AKT) pathway, thereby suggesting its potential as an alternative treatment option for RA [32] (Figure 1, Third panel). The gene discussed is AKT1; the disease is rheumatoid arthritis.